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of Life Inventory Rheumatology Module (PedsQL-R) and
Generic Core Scale (PedsQL-G). Spearman correlations
and regression analysis were done to examine the rela-
tionship between the WTP(A) or WTP(B) and other JIA
outcomes. RESULTS: Fifty-four families of children with
JIA (mean age: 10 yrs) were interviewed. Fifty-four
percent of the patients had some GI discomfort and 
the mean/median number of involved joints was 4.3/2.
WTP rating was refused by ﬁve families (9%). The
mean/median of WTP(A) was $323/$200 and $54/$38
for WTP(B), respectively. After adjustment for the
monthly family income, WTP (A) and WTP (B) were
moderately corrrelated to pain, CHAQ, PedsQL-R 
and PedsQL-G (r = 0.35–0.47). CONCLUSIONS: WTP
appears to be a promising, easy to use method for assess-
ing health care preferences in JIA. WTP is feasible and
has construct validity in JIA. Further validation in a larger
group of patients is warranted.
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OBJECTIVE: To quantify GI symptoms of children with
JIA using the Gastrointestinal Symptom Scale for Pedi-
atrics (GIPS), to verify for the GIPS reliability, construct
validity and quality of parent proxy reporting, and to
evaluate the relationship of GI symptoms severity and
HRQL in JIA. METHODS: A convenience sample of 54
families of JIA patients was interviewed twice (patients
(pts) >7 yrs, 1 parent per family). GI symptom severity
was measured by the GIPS (7 item scale with yes/no
answers; score 0 - 7; 0 = no GI symptoms) and a visual
analog scale (VAS-GI). Information on other outcomes
was obtained, incl. the Childhood Health Assessment
Questionnaire (CHAQ); the Pediatric Quality of Life
Inventory Rheumatology Module (PedsQL-R) and
Generic Core Scale (PedsQL-G). RESULTS: Forty-six
percent of the pts (mean age: 10.3 yrs) had some GI symp-
toms. Treatments included NSAIDs (n = 45), methotrex-
ate (MTX; n = 33) and GI protectants (n = 21). Intrarater
reliability and internal consistency of the GIPS (parent
report: weighted kappa = .7; Crohnbachs-á = 1) were
high; the quality of parent proxy reports was very good
(intraclass corr. coeff. = .7). Scores of the GIPS, GI-VAS,
PedsQL-R and PedsQl-G (r = .5-.8) were strongly corre-
lated. The mean GIPS score of pts having GI symptoms
was 2, with nausea and epigastric pain being most
common. Use of MTX (p < .003) and NSAIDs (p < .03)
led to signiﬁcantly higher and GI protectants to signiﬁ-
cantly lower GIPS scores (p < .008) in univariate analy-
sis. Corrected for the disease severity and activity,
children with moderate/severe GI symptoms (GIPS > 2; n
= 16) had signiﬁcantly lower HRQL (PedsQL-R: p < .005;
PedsQL-G: p < .04) and more disability (CHAQ; p <.005)
compared to patients without GI symptoms. CONCLU-
SION: The GIPS is a reliable and valid measure of GI
symptom severity. GI symptoms are frequent among chil-
dren with JIA and, if moderate or severe, have a signiﬁ-
cant negative impact on the HRQL. GI side effects require
special consideration for patient management and med-
ication choices in JIA.
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OBJECTIVES: Summary physical and mental health
scores for the Short Form (SF) measures assume that
physical and mental health are uncorrelated. The Rand
Health Status Inventory (HSI) measures allow correlation
and also employ item weights derived from item-response
theory. Do these different approaches to scoring matter?
The objective was to compare summary scores using both
the SF and Rand HSI. METHODS: SF-36 and the Health
Utilities Index Mark 3 (HUI3) were administered to a
cohort of patients waiting for elective total hip arthro-
plasty (THA). SF-12 and HUI3 were administered to 
a cohort of high-risk primary-care patients. Summary
scores were generated and compared. Single-attribute
utility scores for emotion in HUI3 were also computed.
Canadian and U.S norms for SF, Rand HSI, and HUI3
were used to interpret results. RESULTS: For THA
patients mean physical health scores were 28 and 36 for
SF and Rand HSI. Mean mental health scores were 55
and 42. For the primary-care patients the scores were 34
and 36 for physical and 46 and 40 for mental health.
HUI3 emotion scores for the primary-care patients were
well below population norm. CONCLUSIONS: SF and
Rand HSI provided similar summary scores in the THA
study. However, SF and Rand HSI mental health scores
differed in the primary-care patient cohort and results
from HUI3 corroborate the mental health deﬁcits identi-
ﬁed by the Rand HSI. It may be wise for investigators to
utilize both SF and Rand HSI scoring systems.
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OBJECTIVES: To utilize WebTV technology to assess the
effect of coexistence of depressive symptomatology on 
the health status of arthritic individuals, in a nationally
representative elderly sample. METHODS: Depression 
in arthritic individuals was measured using the Center 
for Epidemiological Studies Depression scale (CESD-20).
Health related quality of life (HRQOL) was assessed
using Short Form 36 (SF-36) scale. Random Digit Dialing
(RDD) survey procedures were used to recruit individu-
als having different types of arthritis, but having no pre-
viously diagnosed depression (N = 550), drawn from US
households across 44 states. Each participating house-
hold was outﬁtted with a free WebTV and Internet con-
nection. Cut-off score of ≥16 was used on the CESD-20
scale to identify arthritic persons at risk for clinical
depression. CESD-20 and dimension scores such as Neg-
ative Affect (NA), Positive Affect (PA), Somatic Symp-
toms (SS), Interpersonal Problems (IP), Mental Health
(MH), Physical and Mental component Summary scores
(PCS and MCS) were computed. Conceptually relevant
associations between CESD-20 and SF-36 subscales were
determined. RESULTS: A response rate of 87% (N = 480)
was achieved following the administration of surveys in
August 2001. Using CESD scores, 16% (n = 76) of the
respondents were found to be at risk for clinical depres-
sion. Signiﬁcant negative correlations between SS and
PCS scores (r = -0.416, P = 0.000), and between CESD
and MH scores (r = -0.68, P = 0.000) were found. No
signiﬁcant differences on the CESD, SS, PCS, MCS scores
were found across different arthritic types, races, and
gender. However, differences on all these measures were
signiﬁcant (P < 0.05) for the elderly categorized into dif-
ferent subgroups based on age. CONCLUSION: Con-
current administration of SF-36 and CESD-20 in patients
with a chronic disease is recommended for the measure-
ment of depressive symptomatology and health status.
Preliminary examination of associations among crucial
study variables suggests that CESD somatic items may
actually somewhat elevate the depression symptom scores
in arthritis.
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OBJECTIVES: The aim of this study was to determine
utility values for different health outcomes associated
with the use of non-steroidal anti-inﬂammatory drugs
(NSAIDs) or paracetamol in the treatment of osteoarthri-
tis. METHODS: Six physicians and 73 nurses responded
to a postal survey based on the EQ-5D. Health care pro-
fessionals were considered an appropriate survey group
because they have a good understanding of how the alter-
native health state scenarios would impact on patients.
Five health states were deﬁned based on published clini-
cal trial data and expert opinion: 1) osteoarthritis patients
managed with an NSAID who are free of gastrointestinal
complications; 2) osteoarthritis patients managed with 
an NSAID who have minor NSAID-type gastrointestinal
complications (e.g., dyspepsia, reﬂux); 3) osteoarthritis
patients managed with an NSAID who have an uncom-
plicated perforation, ulcer or bleed (PUB); 4) osteo-
arthritis patients managed with an NSAID who have a
complicated PUB; and 5) osteoarthritis patients managed
with paracetamol. Utility values were derived for each of
the ﬁve health states based on the responses to the survey
and the EQ-5D scoring algorithm. RESULTS: Patients
without gastrointestinal side effects had the highest utility
value (mean utility value: 0.667). Patients with compli-
cated PUBs had the lowest utility (-0.151), while higher
utilities were seen in patients with uncomplicated PUBs
(0.456) and those with minor NSAID-type gastrointesti-
nal complications (0.557). Patients whose osteoarthritis
was managed with paracetamol had lower utility than
those patients managed with traditional NSAIDs who are
free of gastrointestinal complications—a result consistent
with the relative efﬁcacy of NSAIDs and paracetamol in
the treatment of osteoarthritis. CONCLUSIONS: Thera-
pies with lower rates of gastrointestinal-related toxicity
can improve the quality of life of osteoarthritis sufferers.
Our study enables new osteoarthritis treatments which
offer lower rates of GI toxicity than traditional NSAIDs
to be evaluated in a cost-utility framework.
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OBJECTIVES: Biochemical failure after deﬁnitive treat-
ment for prostate cancer is common. We determined
second treatment patterns in biochemical failure patients
initially managed with radical prostatectomy (RP) and
radiation (XRT). METHODS: Three hundred eighty-one
and 259 patients managed with RP and XRT, respectively,
who failed biochemically were identiﬁed from CaPSURE,
a national prostate cancer registry. Failure was a PSA >
0.4 after RP and three consecutive rises in PSA above the
nadir for XRT. Logistic regression was used to determine
predictors of second treatment after failure. RESULTS:
Median time to failure was 20.8 and 25.3 months for RP
and XRT. One point twenty-one (32%) and 75 (29%) of
RP and XRT failure patients received second treatment.
Median time between failure and second treatment was
8.2 and 17.6 months for RP and XRT. Second treatments
following RP were hormonal therapy (59%) and XRT
(41%) and for XRT were mainly hormonal therapy
